Name: GENEURO SA (GNRO) Stock
Brand: GENEURO SA
Rating: 3 (3 reviews)

Question 1

What does GNRO do?

Accepted Answer

GeNeuro SA is a clinical stage company, which engages in the research and development of pharmaceutical products. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 19 full-time employees. The company went IPO on 2016-04-15. The firm's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The firm's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.

Question 2

Can you provide the latest stock price for GENEURO SA?

Accepted Answer

The current stock price of GNRO.PA is 0.025 EUR. The price decreased by -8.09% in the last trading session.

Question 3

Does GENEURO SA pay dividends?

Accepted Answer

GNRO.PA does not pay a dividend.

Question 4

What is the ChartMill rating of GENEURO SA stock?

Accepted Answer

GNRO.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.

Question 5

On which exchange is GNRO.PA stock listed?

Accepted Answer

GNRO.PA stock is listed on the Euronext Paris exchange.

GENEURO SA (GNRO.PA) Stock Price, Forecast & Analysis

GNRO.PA Latest News, Press Relases and Analysis